Streptomyces viridochromogenes
INTRODUCTION
Avilamycin A and avilamycin C (Fig. 1 ) are oligosaccharide antibiotics belonging to the orthosomycin group (Buzzetti et al., 1968) . Like ziracin, another orthosomycin, which has been tested in clinical trials against human infectious diseases (Foster & Rybak, 1999 ; Fuchs et al., 1999 ; Jones et al., 1999 ; Lin et al., 2000 ; Wang et al., 2000) , avilamycin is a potent antibiotic with excellent activity against Gram-positive bacteria (Wright, 1979) . The biosynthesis of avilamycin A requires the formation of a polyketide moiety and its attachment to a heptasaccharide chain consisting of -olivose, 2-deoxy--evalose, 4-O-methyl--fucose, 2,6-di-O-methyl--mannose, -lyxose and (methyl) eurekanate. As for many antibiotics, the cloning of the avilamycin biosynthetic genes has been facilitated by the fact that they are organized in a cluster. The complete avilamycin biosynthetic gene cluster has been sequenced and several genes 
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have been characterized (Gaisser et al., 1997 ; Weitnauer et al., 2001) . Expression of one of these genes, encoding a polyketide synthase, in Streptomyces lividans resulted in the production of orsellinic acid. It was also shown that insertional inactivation of a putative dNDP-glucose 4,6-dehydratase gene (aviE1) abolished avilamycin A production. Targeted gene disruption of two other genes, aviG4 and aviH, encoding a methyltransferase and a halogenase, respectively, led to the production of avilamycin derivatives with an incomplete dichloroisoeverninic moiety.
In contrast to avilamycin A, in which a long sugar side chain is connected to a small polyketide moiety, erythromycin is a macrolide polyketide, to which only two separate sugar residues (-mycarose and -desosamine) are transferred (Fig. 1) . The biosynthesis of erythromycin is well understood and many mutants containing deletions in single biosynthetic genes are available (Paulus et al., 1990 ; Haydock et al., 1991 ; Weber et al., 1991 ; Stassi et al., 1993 ; Lambalot et al., 1995 ; Summers et al., 1997 ; Salah-Bey et al., 1998 ; Gaisser et al., 1998 genes, eryBIII, encodes a C-methyltransferase involved in methylation at position C3 during dTDP--mycarose biosynthesis (Gaisser et al., 1998) .
For better understanding of the biosynthesis of avilamycin A we have initiated the characterization of another gene (aviG1) of the avilamycin biosynthetic gene cluster located upstream of the avilamycin polyketide synthase biosynthetic gene. The deduced amino acid sequence of aviG1 was very similar to EryBIII. The involvement of AviG1 in the biosynthesis of avilamycin A was demonstrated by targeted gene disruption and complementation of an eryBIII mutant of Saccharopolyspora erythraea.
METHODS
Bacterial strains, plasmids and culture conditions and materials. Streptomyces viridochromogenes Tu$ 57 (Buzzetti et al., 1968) , obtained from the Department of Microbiology, University of Tu$ bingen, Germany, was grown on 1 % malt extract, 0n4 % yeast extract, 0n4 % glucose and 1 mM CaCl # , pH 7n2 (HA medium) at 37 mC. For production of avilamycins, spores of Str. viridochromogenes Tu$ 57 were transferred to NL19j medium containing 2 % mannitol, 2 % soya flour and 20 mM -valine (pH 7n2) and were grown at 28 mC in 500 ml baffled flasks filled with 100 ml medium at 180 r.p.m. for 48 h. The erythromycin-producing red variant strain of Sac. erythraea NRRL2338 (Hessler et al., 1997) was kindly provided by J. M. Weber, FermaLogic, Chicago, IL, USA. For optimal production of erythromycin A and its derivatives, Sac. erythraea NRRL2338, the eryBIII mutant 335 and the eryBIII mutant 335 containing aviG1 were grown at 30 mC as described previously (Gaisser et al., 1998) . DNA manipulation was performed in Escherichia coli XL-1 Blue MRF from Stratagene. Plasmids were passed through E. coli ET12567 (dam − dcm − hsdS − Cm + ) (Flett et al., 1997) to generate unmethylated DNA before being transferred into Str. viridochromogenes Tu$ 57. E. coli strains were grown under standard conditions. pBluescript SKk (pSKk) was obtained from Stratagene, plasmids pUC18, pUC19 and pSP1, carrying the erythromycin resistance gene (Pelzer et al., 1997) , were provided by S. Pelzer, University of Tu$ bingen, Germany, and pSET152 (Biermann et al., 1992) was obtained from Eli Lilly. The construction of the expression plasmid pSG142 has been described previously (Gaisser et al., 2000) . Plasmids used in this study are listed in Table 1 .
Medium components were purchased from Hartge Ingredients and restriction enzymes were from Amersham Pharmacia. Avilamycin A was a gift from Eli Lilly, carbenicillin was from Roth, and apramycin and erythromycin were from Fluka. All other chemicals were from Roth.
General genetic manipulation. Isolation of E. coli plasmid DNA, digestion of DNA with restriction endonucleases and Southern hybridization were carried out according to the directions of the suppliers of kits, enzymes and reagents (Amersham Pharmacia). Southern hybridization was performed with Hybond-N nylon membranes (Amersham Pharmacia). Probes were labelled with digoxigenin (DIG) by using a DIG labelling and detection kit (Roche). Restriction mapping and other routine molecular biology methods were performed as described by Sambrook et al. (1989) . Protoplast formation, transformation and regeneration of protoplasts from Str. viridochromogenes Tu$ 57 were carried out by standard procedures (Hopwood et al., 1985) . PCR was carried out using a Perkin Elmer GeneAmp 2400 thermal cycler. The conditions were as described by Bechthold & Floss (1994) .
DNA sequencing and computer-assisted sequence analysis.
DNA was sequenced by the dideoxynucleotide chain-termination method using thermosequenase (Amersham Pharmacia). Universal and reverse primers (Amersham Pharmacia) were used. Sequencing reactions were performed on an automated sequencer (Vistra 725) from Molecular Dynamics and on an ABI sequencer from 4-Base Lab. DNA sequences were analysed using the  software package (version 2, 1995 ; Hitachi Software Engineering).  analysis (Altschul et al., 1997) was used to search the GenBank CDC translations j PDB j SWISS-PROT j Spupdate j PIR, release 2.0 for matching sequences.
Generation of a chromosomal aviG1 mutant of Str. viridochromogenes Tu $ 57. For generation of a chromosomal aviG1 mutant of Str. viridochromogenes Tu$ 57 by homologous recombination, plasmid pMIK1 was constructed. A 7n7 kb BamHI fragment containing the entire methyltransferase gene was cloned into pBluescript SKk to create plasmid B7. B7 was digested with BglII and SpeI (the SpeI site is located within the polylinker of pBluescript SKk), treated with Klenow frag- ment and religated to generate pMIK1a. A 2n5 kb SacI fragment of pMIK1a, containing aviG1, was ligated into the corresponding sites of pSP1, generating pSP-MIK (Fig. 2) . pSP-MIK was digested with NcoI to delete a 285 bp fragment within aviG1, resulting in plasmid pMIK1. pMIK1 was used to transform protoplasts of Str. viridochromogenes Tu$ 57. Selection of primary transformants was performed on erythromycin-containing plates. For characterization of transformants by Southern hybridization, an internal 1n7 kb SmaI fragment of the ermE gene of pSP1 and the internal 2n2 kb SacI fragment of pMIK1 were used as probes. After screening for erythromycin-sensitivity, a double cross-over mutant, named Str. viridochromogenes GW1, was obtained. Chromosomal DNA from this mutant was analysed by Southern hybridization using the 2n2 kb SacI fragment as probe. The result of Southern hybridization was confirmed by PCR using oligonucleotide primers HaloF (5h-GCCGAGC-AAAGCTTGGAGAATCAT-3h) and HaloR (5h-TGGTGG-CATGCGATGTCACCTCC-3h).
Complementation of mutant Str. viridochromogenes GW1.
For complementation of mutant Str. viridochromogenes GW1, plasmid pSET-G1erm was constructed. pUWLurdGT1c (Trefzer et al., 2000) was subjected to a KpnI\XbaI restriction digestion to obtain a 1n6 kb fragment that covers the complete reading frame urdGT1c as well as the ermE promoter sequence. This fragment was inserted in the multiple cloning site of pUC19 cleaved with the same enzymes. This plasmid was named pUC19-1cerm. The urdGT1c gene and the ermE promoter were excised by EcoRI restriction and ligated into pSET152 to create plasmid pSET-1cerm. aviG1 was PCRamplified to introduce MunI and XbaI restriction sites by using oligonucleotide primers AviG1F (5h-AGATGTCAAT-TGCTGGCTCA-3h) and AviG1R (5h-TGGTGTCTAGAGA-TGTCACCTCC-3h (restriction sites are underlined). Plasmid pSET-1cerm was digested with MunI and XbaI to remove urdGT1c, and aviG1 was cloned behind the ermE promoter in place of urdGT1c to create the integration plasmid pSETG1erm. After transformation of mutant Str. viridochromogenes GW1 by pSET-G1erm, several colonies were obtained and grown at 28 mC in liquid medium as described above. Extracts of cultures were analysed by TLC, bioassay and HPLC-UV (see Fig. 4 ).
Complementation of the erythromycin eryBIII mutant 335.
For complementation of the eryBIII mutant 355, a HindIII restriction site 5h to the ribosome-binding site and an SphI restriction site 3h to the termination codon were introduced into aviG1 by using PCR. The fragment was cloned into the HindIII and SphI sites of pUC18 to generate pUCB, which was digested with HindIII, followed by a fill-in reaction (Sambrook et al., 1989) . After BamHI digestion, the fragment harbouring aviG1 was ligated into pSG142, previously digested with NdeI, followed by treatment with Klenow polymerase and BglII digestion. The cloning region around the former NdeI site in the resulting plasmid, pSGaviG1, was sequenced, revealing the deletion of 9 nt at the NdeI\HindIII fusion site. Plasmid pSGaviG1 was used to transform the Sac. erythraea eryBIII mutant 335 as described by Gaisser et al. (1998) . The presence of the eryBIII mutation was confirmed using chromosomal DNA of a Sac. erythraea eryBIII mutant and the transformed strain containing aviG1 as template. PCR reactions were carried out as described previously (Gaisser et al., 1998) ; non-linear gradient, 0-100 % solvent B over 16 min at a flow rate of 1n2 ml min − ". Avilamycin A was identified by comparison with an authentic sample. For erythromycin A production, culture supernatants were treated as described previously and the extracts were analysed using electrospray MS (ES-MS ; Gaisser et al., 1998) .
RESULTS AND DISCUSSION

Sequence analysis
Having cloned and sequenced the avilamycin biosynthetic gene cluster (Gaisser et al., 1997 ; Weitnauer et al. 2001) , our work now was aimed at characterizing further genes involved in avilamycin biosynthesis. Database comparison with the deduced product of aviG1 using  and  revealed similarities between AviG1 and several C-methyltransferases. The most similar proteins found were TylCIII from Streptomyces fradiae (66 % identical amino acids ; Bate et al., 2000) and EryBIII from Sac. erythraea (64 % identical amino acids ; Haydock et al., 1991 ; Gaisser et al., 1998) . Homology was also found to ORF14 from the chloroeremomycin producer Amycolatopsis orientalis (29 % identical amino acids ; Chen et al., 2000) . The C-methyltrans- ferase activity of this enzyme has been demonstrated. AviG1, TylCIII, EryBIII and ORF14 contain three sequence regions which are usually found in S-adenosylmethionine-dependent methyltransferases (Kagan & Clarke, 1994) (Fig. 3) . Motif I, which has been defined as a nine residue block with the consensus sequence (V\I\L)(L\V)(D\E)(V\I)G(G\C)G(T\P)G, is located at position 111-120 in AviG1 (VVDIGSNDG) with a conserved glycine residue at position 5. This motif has been suggested to be a possible component of the Sadenosylmethionine-binding site (Schluckebier et 
1995
). An aspartate as a conserved acidic residue is found 17 residues C-terminal to this motif, which is characteristic for methyltransferases and which, as the crystal structures indicate, makes contact with bound Sadenosylmethionine (Schluckebier et al., 1995) . Putative second and third motifs are indicated in Fig. 3 .
Inactivation of the aviG1 gene
To assay the role of aviG1 in avilamycin biosynthesis, pMIK1 was constructed containing aviG1 with an inframe deletion. After transformation of Str. viridochromogenes Tu$ 57 by pMIK1, several erythromycinresistant colonies were obtained. Integration of pMIK1 into the chromosome at the expected position was verified by Southern hybridization (data not shown). To allow for the second recombination event, integrants were screened for erythromycin sensitivity. The chromosomal mutation in mutant Str. viridochromogenes GW1, which showed erythromycin sensitivity, was analysed by Southern hybridization (data not shown). The internal 2n2 kb SacI fragment of pMIK1 was used to probe EcoRI-digested chromosomal DNA. Analysis of the wild-type Str. viridochromogenes Tu$ 57 showed one signal consisting of the two expected fragments of 1n7 kb after hybridization. When chromosomal DNA from clone Str. viridochromogenes GW1 was treated in the same way, two hybridization signals were obtained, one of 1n7 kb and one of 1n5 kb, indicating that the 285 bp NcoI fragment was deleted. To confirm the presence of the deletion within the chromosome of Str. viridochromogenes GW1, chromosomal DNA of the mutant and the wild-type strain was subjected to PCR analysis. The size of the amplified fragment (0n9 kb) detected in the mutant strain was identical to that generated with the inactivation construct pMIK1, while the wild-type strain gave a PCR product of the expected higher size (1n2 kb) (data not shown). The products accumulated by this mutant were also analysed for antibacterial activity. After cultivation of the mutant, culture supernatants were extracted as described in Methods and the extract was tested for antibiotic activity against Bacillus subtilis.
No inhibitory effect on the growth of B. subtilis was observed for the pMIK1 mutant extract, but extracts of the wild-type showed inhibitory effects. In addition, TLC and HPLC analysis of the extract of mutant Str. viridochromogenes GW1 did not reveal the presence of any avilamycin derivatives (Fig. 4) . Assuming that AviG1 is responsible for methylation at position C3 during 2-deoxy--evalose biosynthesis, an explanation for the breakdown of avilamycin biosynthesis could be that either the synthesis of evalose or the attachment of this sugar is blocked in the methyltransferase mutant. We also did not detect any orsellinic acid derivative in the mutant. We assume that the expression of aviM, encoding an orsellinic acid synthase, is suppressed in the absence of the saccharide moiety.
Complementation of mutant Str. viridochromogenes GW1
To determine clearly that the mutation event only affected the desired gene and not other genes, aviG1 was ligated downstream of the ermE up-promoter, cloned into the integration plasmid pSET152 and introduced by protoplast transformation into the corresponding GW1 mutant. Analysis of extracts of complemented mutants by TLC and HPLC-UV clearly showed that avilamycin C and avilamycin A production was restored (Fig. 4) . Thus, we could rule out any upstream or downstream effects.
Complementation of the erythromycin eryBIII mutant 335
To demonstrate the complementation of the Sac. erythraea eryBIII mutant 335, plasmid pSGaviG1 was isolated which places the expression of aviG1 under the control of the activator ActII-ORF4 (Rowe et al., 1998) . Extracts of culture supernatants of the wild-type strain, eryBIII mutant 355 and eryBIII mutant 355 containing aviG1 were analysed by ES-MS. Extracts of the wildtype strain gave the expected signal for erythromycin A at m\z 734n7. Mutant 355 gave a signal at m\z 720n7, which indicates the formation of 3d-C-desmethyl erythromycin A (Gaisser et al., 1998) . The MS data obtained with the eryBIII mutant 355 containing aviG1 showed peaks at m\z 720n7 and 734n7, indicating that erythromycin A as well as 3d-C-desmethyl erythromycin A are formed (Fig. 5) . To confirm that methylation occurred at 3d-C of -mycarose, MS\MS analyses of the peaks at m\z 734n7 and m\z 720n7 were performed. In both cases, a daughter ion at m\z 576n5 was detected unambiguously, indicating the loss of the 3d-C sugar (data not shown). From these data we can conclude that the expression of aviG1 did allow complementation of the eryBIII mutation. AviG1 seems to be able to participate in -mycarose biosynthesis, providing further support for the proposal that AviG1 encodes a Cmethyltransferase capable of acting on position C3 of an activated sugar. Since -mycarose and 2-deoxy--evalose differ mainly in their stereochemistry at position C5, AviG1 is therefore most likely involved in the synthesis of 2-deoxy--evalose. However, results using bioassays revealed that the expression of aviG1 restored erythromycin production just to a very small extent (data not shown). No reproducible difference could be detected between the size of the haloes of Sac. erythraea 335 and Sac. erythraea 335 expressing aviG1 (data not shown).
